Study Feasibility and Site Selection

Balancing Urban vs Rural Site Selection

Posted on digi By digi

The decision to select urban versus rural sites in clinical trials affects nearly every operational parameter—from patient recruitment and retention to compliance, cost, and regulatory feasibility. While urban sites offer infrastructure, speed, and scalability, rural sites offer access to underrepresented populations and diversity in trial data. Sponsors must carefully balance both to ensure successful execution and equitable trial access.
Click to read the full article.

Geographic and Demographic Considerations, Study Feasibility and Site Selection

Using Epidemiological Data in Geographic Planning

Posted on digi By digi

Geographic planning for site selection is no longer driven by logistical convenience or investigator relationships alone. Sponsors today rely on robust epidemiological data—such as disease prevalence, incidence, and regional burden—to identify high-opportunity locations for clinical trials. By aligning site geography with epidemiological trends, feasibility teams can optimize patient access, accelerate recruitment, and improve the statistical power and diversity of clinical data.
Click to read the full article.

Geographic and Demographic Considerations, Study Feasibility and Site Selection

Transportation and Accessibility in Site Feasibility

Posted on digi By digi

Transportation and accessibility have become critical considerations in clinical trial site feasibility, especially as studies increasingly focus on patient-centric design and diversity in enrollment. A site that is difficult to reach—due to poor transit, long travel times, or geographic isolation—poses challenges for both subjects and clinical research associates (CRAs). It can lead to screen failures, missed visits, high dropout rates, and noncompliance with scheduled assessments.
Click to read the full article.

Geographic and Demographic Considerations, Study Feasibility and Site Selection

Site Location’s Role in Diverse Patient Enrollment

Posted on digi By digi

Diversity in clinical trial enrollment is now a regulatory priority, a scientific necessity, and an ethical obligation. Yet, one of the most overlooked factors influencing diversity is site location. Where a trial is conducted has a direct impact on who has access to participate. Sponsors that select sites in non-diverse or high-barrier regions often fail to recruit a representative population, leading to biased outcomes and delayed regulatory approval.
Click to read the full article.

Geographic and Demographic Considerations, Study Feasibility and Site Selection

Local Regulatory Environments and Site Operations

Posted on digi By digi

Site operations in clinical trials are governed not only by internal SOPs and global sponsor protocols but also by the local regulatory environment in which each site operates. National laws, ethics committee expectations, drug import controls, documentation requirements, and investigator obligations can vary significantly across jurisdictions—and even within countries. These variations impact startup timelines, operational compliance, and risk exposure for both sponsors and contract research organizations (CROs).
Click to read the full article.

Geographic and Demographic Considerations, Study Feasibility and Site Selection

Cultural Competency in Demographic Targeting

Posted on digi By digi

In the global landscape of clinical research, patient diversity is not just a compliance metric—it’s an ethical imperative and a scientific necessity. However, demographic targeting in feasibility planning often overlooks a critical dimension: culture. Culture influences how individuals perceive healthcare, research, trust, consent, and communication. Ignoring cultural context in recruitment, site training, and communication materials can severely limit access, increase dropout, and distort data.
Click to read the full article.

Geographic and Demographic Considerations, Study Feasibility and Site Selection

Climate and Geography: Impact on Study Design

Posted on digi By digi

In the age of globalized clinical research, trials are no longer confined to homogeneous regions. Sponsors are increasingly deploying multicenter studies across climates—from equatorial humidity to arctic frost, from high-altitude cities to flood-prone deltas. Yet, many trial designs still assume environmental uniformity. Climate and geography directly impact protocol design, subject safety, IMP stability, site feasibility, and even regulatory expectations.
Click to read the full article.

Geographic and Demographic Considerations, Study Feasibility and Site Selection

Mapping Disease Burden to Site Locations

Posted on digi By digi

In clinical research, finding the right patients in the right places is fundamental to trial success. Site selection that does not align with disease epidemiology risks under-recruitment, poor data diversity, and increased trial costs. Mapping disease burden—through prevalence, incidence, and burden indicators like Disability-Adjusted Life Years (DALYs)—allows sponsors to locate patient-rich geographies and design studies that are both operationally feasible and scientifically robust.
Click to read the full article.

Geographic and Demographic Considerations, Study Feasibility and Site Selection

Evaluating Investigator Experience with Similar Studies

Posted on digi By digi

In the site feasibility phase of clinical trials, one of the most predictive indicators of site performance is the principal investigator’s (PI) experience with studies of comparable design, indication, and complexity. Selecting an investigator with aligned experience increases the probability of timely recruitment, protocol adherence, data quality, and regulatory compliance. Conversely, mismatched or underqualified investigators can lead to delays, protocol deviations, and even regulatory inspection findings.
Click to read the full article.

PI (Principal Investigator) Experience Evaluation, Study Feasibility and Site Selection

How to Review PI CVs for Regulatory Submission

Posted on digi By digi

One of the essential documents in any clinical trial regulatory submission—whether to the FDA, EMA, DCGI, or local ethics committee—is the Principal Investigator’s (PI) curriculum vitae (CV). A well-documented and accurate CV demonstrates the PI’s qualifications, experience, and capability to conduct the proposed study. Regulatory bodies rely on this document to ensure that individuals conducting human research are qualified by education, training, and experience, as per ICH-GCP E6(R2) standards.
Click to read the full article.

PI (Principal Investigator) Experience Evaluation, Study Feasibility and Site Selection